It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...
The Aldosterone Blockade for Health Improvement Evaluation in End-Stage Renal Disease (ACHIEVE) Trial: Rationale and Clinical Research Protocol - Michael Walsh, David Collister, Martin Gallagher, Patr...
Background: The mineralocorticoid aldosterone may contribute to the risk of cardiovascular morbidity and mortality in patients receiving maintenance dialysis. W...
journals.sagepub.com
June 5, 2025 at 7:44 AM
It's been a long journey but today we can share the methods and rationale for the #ACHIEVEtrial (Spiro vs placebo for patients with kidney failure receiving maintenance dialysis) and tomorrow we share the results at #era25
journals.sagepub.com/doi/10.1177/...
journals.sagepub.com/doi/10.1177/...